Tag Archive for: ESMO 2025

For the first time taking place in Berlin: ESMO 2025BIOCOM Interrelations
ESMO 2025

Tubulis presents first clinical data on ADC TUB-040

Following its US$361 m Series C financing, Tubulis AG presented first Phase I/IIa data on its lead ADC, TUB-040, at ESMO 2025 in Berlin. The study focuseds on patients with platinum-resistant ovarian cancer (PROC). TUB-040 shows clear differentiation potential

Read more